Canopy Growth (CGC) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Canopy Growth (CGC) has outperformed Citius Oncology (CTOR) over the past year, losing 44.7% versus a loss of 54.6%. Canopy Growth is the larger company by market cap ($380.5 million vs $88.3 million), about 4.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | CTOR |
|---|---|---|
| Share price | $0.8468 | $0.835 |
| Market cap | $380.47M | $88.31M |
| 1-day change | -3.39% | -2.45% |
| YTD return | -25.72% | -16.50% |
| 1-year return | -44.65% | -54.62% |
| 5-year return | -99.37% | — |
| EPS (TTM) | $-0.45 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $2.25 |
| 52-week low | $0.81 | $0.491 |
| Distance from 52-week high | -64.42% | -62.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +41.71% | +379.04% |
| Average volume | 2.77M | 99.72K |
| Shares outstanding | 423.04M | 105.76M |
| Employees | 1,128 | — |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Canopy Growth is about 4.3 times larger than Citius Oncology by market value ($380.47M vs $88.31M).
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,128 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Healthcare · Drug Manufacturers - Specialty & Generic
CGC vs CTOR FAQ
Which is bigger, Canopy Growth or Citius Oncology?
Canopy Growth (CGC) is larger, with a market capitalization of $380.47M compared with $88.31M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CGC or CTOR?
CGC returned -44.65% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Citius Oncology in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.